Skip to main navigation Skip to search Skip to main content

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE OR TRANSPLANT-DEFERRED PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date2/04/23 → 1/04/26

Keywords

  • Clinical Trials
  • Multiple Myeloma

Clinical Trial Phase

  • Phase III (a & b)